Aurobindo Pharma gains after its JV receives SEC recommendation for pneumococcal 15 valent vaccine
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Aurobindo Pharma is currently trading at Rs. 442.75, up by 5.50 points or 1.26% from its previous closing of Rs. 437.25 on the BSE.
The scrip opened at Rs. 440.40 and has touched a high and low of Rs. 444.80 and Rs. 438.40 respectively. So far 102108 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 742.25 on 11-Jan-2022 and a 52 week low of Rs. 434.40 on 26-Dec-2022.
Last one week high and low of the scrip stood at Rs. 459.80 and Rs. 434.40 respectively. The current market cap of the company is Rs. 25933.64 crore.
The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 37.97% and 10.20% respectively.
Aurobindo Pharma’s Joint Venture (JV) company-- Tergene Biotech has received Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) recommendation to manufacture and market 15-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV15) with three dose schedule (3 +0) for administration into the pediatric age group of 6, 10 and 14 weeks.
PCV15 vaccine was developed by Tergene Biotech and manufactured at AuroVaccines, which is a wholly owned subsidiary of Aurobindo Pharma with capabilities in vaccines development and manufacturing. Aurobindo Pharma holds 80% stake in the Joint Venture company, Tergene Biotech.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
